Organization | Ivy Brain Tumor Center

Ivy Brain Tumor Center Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial

2018

NCT03834740

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Alternative names

Chief Scientific Officer/Director of the Ivy Brain Tumor Center | Deputy Director of the Ivy Brain Tumor Center | Ivy Brain Tumor Center | Ivy Center for Advanced Brain Tumor Treatment

Active Ingredients

Drugs in Phase 2 Trials (1)

abemaciclib (verzenio) (2 trials)

Drugs in Phase 1 Trials (11)

azd1390 (1 trial)

bdtx-1535 (1 trial)

everolimus (zortress) (1 trial)

infigratinib (Truseltiq) (1 trial)

ly3214996 (1 trial)

niraparib (zejula) (1 trial)

olaparib (lynparza) (1 trial)

pamiparib (1 trial)

ribociclib (kisqali) (1 trial)

temozolomide (temodar) (1 trial)

temsirolimus (torisel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 9
# of Trial APIs: 12